西藏药业
(600211)
| 流通市值：116.52亿 | | | 总市值：116.52亿 |
| 流通股本：3.22亿 | | | 总股本：3.22亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 1,554,436,303.07 | 723,548,218.03 | 2,981,538,230.43 | 2,089,270,909.97 |
| 营业总成本 | 1,092,056,208.13 | 502,684,914.58 | 1,988,734,371.46 | 1,324,837,999.8 |
| 其他经营收益 | | | | |
| 营业利润 | 636,374,380.95 | 316,296,922.74 | 1,043,831,968.47 | 811,884,831.52 |
| 利润总额 | 636,945,067.83 | 316,636,987.52 | 1,040,617,869.2 | 810,453,885.42 |
| 净利润 | 571,128,354.71 | 282,833,468.95 | 916,980,955.72 | 725,906,851.38 |
| 每股收益 | | | | |
| 其他综合收益 | -23,721,415.55 | -12,073,799.08 | -17,441,769.97 | -13,885,663.2 |
| 综合收益总额 | 547,406,939.16 | 270,759,669.87 | 899,539,185.75 | 712,021,188.18 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 4,895,649,487.39 | 4,795,724,455.11 | 4,637,316,550.09 | 4,145,524,169.56 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,543,865,823.42 | 1,596,088,521.79 | 1,630,070,617.82 | 1,670,802,345.81 |
| 资产总计 | 6,439,515,310.81 | 6,391,812,976.9 | 6,267,387,167.91 | 5,816,326,515.37 |
| 流动负债: | | | | |
| 流动负债合计 | 1,702,873,823 | 1,662,701,716.89 | 1,640,125,995.34 | 1,372,670,180.73 |
| 非流动负债: | | | | |
| 非流动负债合计 | 512,704,431.62 | 501,358,427.21 | 489,779,958.59 | 502,898,730.66 |
| 负债合计 | 2,215,578,254.62 | 2,164,060,144.1 | 2,129,905,953.93 | 1,875,568,911.39 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 3,913,459,051.22 | 3,899,996,548.04 | 3,798,429,273.3 | 3,551,437,102.21 |
| 股东权益合计 | 4,223,937,056.19 | 4,227,752,832.8 | 4,137,481,213.98 | 3,940,757,603.98 |
| 负债和股东权益合计 | 6,439,515,310.81 | 6,391,812,976.9 | 6,267,387,167.91 | 5,816,326,515.37 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 2,017,330,557.84 | 1,140,989,052.39 | 3,280,245,803.15 | 2,577,290,963.79 |
| 经营活动现金流出小计 | 1,538,173,455.25 | 757,538,069.72 | 2,275,494,997.23 | 1,864,226,050.89 |
| 经营活动产生的现金流量净额 | 479,157,102.59 | 383,450,982.67 | 1,004,750,805.92 | 713,064,912.9 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 2,829,438,905.11 | 1,326,273,251.13 | 4,554,882,655.3 | 3,330,412,806.08 |
| 投资活动现金流出小计 | 3,283,750,939.62 | 1,699,053,183.6 | 5,143,957,010.34 | 3,930,974,808.09 |
| 投资活动产生的现金流量净额 | -454,312,034.51 | -372,779,932.47 | -589,074,355.04 | -600,562,002.01 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 1,039,062,405.85 | 327,121,130.21 | 1,009,797,193.37 | 816,728,712.81 |
| 筹资活动现金流出小计 | 1,153,704,245.21 | 229,185,029.34 | 1,132,420,354.43 | 778,461,969.8 |
| 筹资活动产生的现金流量净额 | -114,641,839.36 | 97,936,100.87 | -122,623,161.06 | 38,266,743.01 |
| 汇率变动对现金及现金等价物的影响 | -16,251,799.71 | -21,090,592.86 | -22,454,136.39 | -1,319,965.01 |
| 现金及现金等价物净增加额 | -106,048,570.99 | 87,516,558.21 | 270,599,153.43 | 149,449,688.89 |
| 期末现金及现金等价物余额 | 1,470,451,748.49 | 1,664,016,877.69 | 1,576,500,319.48 | 1,455,350,854.94 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -106,048,570.99 | - | 270,599,153.43 | - |
最新报告期：2026-08-20| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 首创证券 | 王斌 | 3.09 | 2.91 | 3.10 | 2026-08-20 |
| 西南证券 | 杜向阳 | 3.23 | 3.44 | 3.58 | 2026-08-18 |